Tumor necrosis factor-α acts reciprocally with solute carrier family 26, member 3, (downregulated-in-adenoma) and reduces its expression, leading to intestinal inflammation

Ding,Xiangming; Li,Dongxiao; Li,Mengke; Tian,Dean; Yu,Hongbing; Yu,Qin

doi:10.3892/ijmm.2017.3347

Tumor necrosis factor-α acts reciprocally with solute carrier family 26, member 3, (downregulated-in-adenoma) and reduces its expression, leading to intestinal inflammation

Authors:
- Xiangming Ding
- Dongxiao Li
- Mengke Li
- Dean Tian
- Hongbing Yu
- Qin Yu
View Affiliations

Affiliations: Department of Gastroenterology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Pediatrics, BC Children's Hospital and The University of British Columbia, Vancouver, BC V6T 1Z4, Canada
Published online on: December 22, 2017 https://doi.org/10.3892/ijmm.2017.3347
Pages: 1224-1232
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Solute carrier family 26, member 3 (Slc26a3), also termed downregulated-in-adenoma (DRA) is a member of the Slc26 family of anion transporters and is mutated in congenital chloride diarrhea. Our previous study demonstrated that DRA deficiency is associated with severely reduced colonic HCO3‑ secretion, a loss of colonic fluid absorption, a lack of a firmly adherent mucus layer and a severely reduced colonic mucosal resistance to dextran sodium sulfate (DSS) damage. However, the direct effect of mediators that trigger intestinal inflammatory factors on DRA has not been fully investigated. Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease. However, to the best of our knowledge, whether TNF‑α acts reciprocally with DRA leading to the development of gut inflammation in IBD has not been reported. The present study identified that the expression level of DRA was reduced in active UC patients and DSS‑induced colitis mice with high expression levels of TNF‑α identified in the peripheral blood serum. In addition, TNF‑α may affect the expression level of DRA in human colonic Caco2BBE cells in a dose‑dependent manner, including in DRA overexpressed Caco2BBE cells. Furthermore, knockdown of TNF‑α in Caco2BBE cells led to a higher expression level of DRA and a markedly reduced secretion of TNF‑α in the culture media. In addition, knockdown of DRA in Caco2BBE cells led to a higher secretion of TNF‑α in the culture media compared with the control cells, which could be reversed by overexpression of DRA. Overall, these results indicate that TNF‑α may act reciprocally with DRA, leading to the development of intestinal inflammation. Based on the pivotal position of TNF‑α in IBD, DRA is hypothesized to have therapeutic potential against colitis serving as an important target.

View Figures

View References

1	Chi KR: Epidemiology: Rising in the East. Nature. 540:S100–S102. 2016. View Article : Google Scholar : PubMed/NCBI
2	Nq SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, et al: Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 145:158–165.e2. 2013. View Article : Google Scholar
3	Wang YF, Ouyang Q and Hu RW: Progression of inflammatory bowel disease in China. J Dig Dis. 11:76–82. 2010. View Article : Google Scholar : PubMed/NCBI
4	Dixon LJ, Kabi A, Nickerson KP and McDonald C: Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 21:912–922. 2015. View Article : Google Scholar : PubMed/NCBI
5	Park JH, Peyrin-Biroulet L, Eisenhut M and Shin JI: IBD immunopahogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 16:416–426. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O’Morain C, Moum B and Colombel JF; Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD): Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 62:630–649. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xia W, Yu Q, Riederer B, Singh AK, Engelhardt R, Yeruva S, Song P, Tian DA, Soleiman M and Seidler U: The distinct roles of anion transporters Slc26a3 (DRA) and Slc26a6 (PAT-1) in fluid and electrolyte absorption in the murine small intestine. Pflugers Arch. 466:1541–1556. 2014. View Article : Google Scholar :
8	Wedenoja S, Pekansaari E, Höglund P, Mäkelä S, Holmberg C and Kere J: Update on SLC26A3 mutations in congenital chloride diarrhoea. Hum Mutat. 32:715–722. 2011. View Article : Google Scholar : PubMed/NCBI
9	Wedenoja S, Höglund P and Holmberg C: Review article: The clinical management of congenital chloride diarrhoea. Aliment Pharmacol Ther. 31:477–485. 2010. View Article : Google Scholar
10	Xiao F, Yu Q, Li J, Johansson ME, Singh AK, Xia W, Riederer B, Engelhardt R, Montrose M, Soleimani M, et al: Slc26a3 deficiency is associated with loss of colonic HCO3 (−) secretion, absence of a firm mucus layer and barrier impairment in mice. Acta Physiol (Oxf). 211:161–175. 2014. View Article : Google Scholar
11	Farkas K, Yeruva S, Rakonczay Z Jr, Ludolph L, Molnar T, Nagy F, Szepes Z, Schnur A, Wittmann T, Hubricht J, et al: New therapeutic targets in ulcerative colitis: The importance of ion transporters in the human colon. Inflamm Bowel Dis. 17:884–898. 2011. View Article : Google Scholar
12	Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Knight SC and Hart AL: Mechanisms of action of anti-tumor necrosis factor-α agents in Crohn’s disease. Inflamm Bowel Dis. 19:1546–1555. 2013. View Article : Google Scholar : PubMed/NCBI
13	Günther C, Neumann H, Neurath MF and Becker C: Apoptosis, necrosis and necroptosis: Cell death regulation in the intestinal epithelium. Gut. 62:1062–1071. 2013. View Article : Google Scholar
14	Fries W, Muja C, Crisafulli C, Cuzzocrea S and Mazzon E: Dynamics of enterocyte tight junctions: Effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol. 294:G938–G947. 2008. View Article : Google Scholar : PubMed/NCBI
15	Xiao F, Juric M, Li J, Riederer B, Yeruva S, Singh AK, Zheng L, Glage S, Kollias G, Dudeja P, et al: Loss of downregulated in adenoma (DRA) impairs mucosal HCO3(−) secretion in murine ileocolonic inflammation. Inflamm Bowel Dis. 18:101–111. 2012. View Article : Google Scholar
16	Juric M, Xiao F, Amashen S, May O, Wahl K, Bantel H, Manns MP, Seidler U and Bachmann O: Increased epithelial permeability is the primary cause for bicarbonate loss in inflamed murine colon. Inflamm Bowel Dis. 19:904–911. 2013. View Article : Google Scholar : PubMed/NCBI
17	Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E and Borgen L: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 92:1894–1898. 1987. View Article : Google Scholar : PubMed/NCBI
18	Yeruva S, Chodisetti G, Luo M, Chen M, Cinar A, Ludolph L, Lünnemann M, Goldstein J, Singh AK, Riederer B, et al: Evidengce for a causal link between adaptor protein PDZK1 downregulation and Na⁺/H⁺ exchanger NHE3 dysfunction in human and murine colitis. Pflugers Arch. 467:1795–1807. 2015. View Article : Google Scholar
19	Yu Q, Liu ZY, Chen Q and Lin JS: Mcl-1 as a potential therapeutic target for human hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci. 36:494–500. 2016. View Article : Google Scholar : PubMed/NCBI
20	Liva KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Kolios G: Animal models of inflammatory bowel disease: How useful are they really? Curr Opin Gastroenterol. 32:251–257. 2016. View Article : Google Scholar : PubMed/NCBI
22	Priyamvada S, Gomes R, Gill RK, Saksena S, Alfefai WA and Dudeja PK: Mechanisms underlying dysregulation of electrolyte absorption in inflammatory bowel disease associated diarrhea. Inflamm Bowel Dis. 21:2926–2935. 2015. View Article : Google Scholar : PubMed/NCBI
23	Barkas F, Liberopoulos E, Kei A and Elisaf M: Electrolyte and acid-base disorders in inflammatory bowel disease. Ann Gastroenterol. 26:23–28. 2013.PubMed/NCBI
24	Yang H, Jiang W, Furth EE, Wen X, Katz JP, Sellon RK, Silberg DG, Antalis TM, Schweinfest CW and Wu GD: Intestinal inflammation reduces expression of DRA, a transporter responsible for congential chloride diarrhea. Am J Physiol. 275:G1445–G1453. 1998.PubMed/NCBI
25	Gill RK, Borthakur A, Hodges K, Turner JR, Clayburgh DR, Saksena S, Zaheer A, Ramaswamy K, Hecht G and Dudeja PK: Mechanisms underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli. J Clin Invest. 117:428–437. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kumar A, Anbazhagan AN, Coffing H, Chatterjee I, Priyamvada S, Gujral T, Saksena S, Gill RK, Alrefai WA, Borthakur A and Dudeja PK: Lactobacillus acidphilus counteracts inhibition of NHE3 and DRA expression and alleviates diarrheal phenotype in mice infected with Citrobacter rodentium. Am J Physiol Gastrointest Liver Physiol. 311:G817–G826. 2016. View Article : Google Scholar
27	Alrefai WA, Wen X, Jiang W, Katz JP, Steinbrecher KA, Cohen MB, Williams IR, Dudeja PK and Wu GD: Molecular cloning and promoter analysis of downregulated in adenoma (DRA). Am J Physiol Gastrointest Liver Physiol. 293:G923–G934. 2007. View Article : Google Scholar : PubMed/NCBI
28	Saksena S, Singla A, Goyal S, Katyal S, Bansal N, Gill RK, Alrefai WA, Ramaswamy K and Dudeja PK: Mechanisms of transcriptional modulation of the human anion exchanger SLC26A3 gene expression by IFN-{gamma}. Am J Physiol Gastrointest Liver Physiol. 298:G159–G166. 2010. View Article : Google Scholar
29	Olesen CM, Coskun M, Peyrin-Biroulet L and Nielsen OH: Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel disease. Pharmacol Ther. 159:110–119. 2016. View Article : Google Scholar : PubMed/NCBI
30	Soufli I, Toumi R, Rafa H and Touil-Boukoffa C: Overview of cytokines and nitric oxide involvement in immune-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 7:353–360. 2016. View Article : Google Scholar : PubMed/NCBI
31	Strober W and Fuss IJ: Proinflammatory cytokine in the pathogenesis of inflammatory bowel disease. Gastroenterology. 140:1756–1767. 2011. View Article : Google Scholar : PubMed/NCBI
32	te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW and van Deventer SJ: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 13:325–330. 2007. View Article : Google Scholar : PubMed/NCBI
33	Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A and Zucco F: The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 21:1–26. 2005. View Article : Google Scholar : PubMed/NCBI
34	Wang H, Chao K, Ng SC, Bai AH, Yu Q, Yu J, Li M, Cui Y, Chen M, Hu JF and Zhang S: Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 17:582016. View Article : Google Scholar : PubMed/NCBI
35	Schaubeck M and Haller D: Reciprocal interaction of diet and microbiome in inflammatory bowel disease. Curr Opin Gastroenterol. 31:464–470. 2015. View Article : Google Scholar : PubMed/NCBI
36	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
37	Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A and Thakkar RB: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 142:257–265.e1-3. 2012. View Article : Google Scholar
38	Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al: Maintenance infliximab for Crohn’s disease: The ACCENT 1 randomized trial. Lancet. 359:1541–1549. 2002. View Article : Google Scholar : PubMed/NCBI